<i>In Vitro</i> Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems
James A. Karlowsky, Meredith Hackel, Samuel K. Bouchillon, Daniel F. Sahm
Abstract
WCK 5222 (cefepime-zidebactam, 2 g + 1g, every 8 h [q8h]) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined the in vitro susceptibility of 1,385 clinical isolates of non-carbapenem-susceptible Enterobacterales , MDR Pseudomonas aeruginosa (also non-carbapenem susceptible), Stenotrophomonas maltophilia , and Burkholderia spp.
Topics & Concepts
CefepimeMicrobiologyStenotrophomonas maltophiliaBacilliPseudomonas aeruginosaBurkholderiaCarbapenemBiologyMedicineAntibioticsBacteriaImipenemAntibiotic resistanceGeneticsAntibiotic Resistance in BacteriaInfections and bacterial resistanceBurkholderia infections and melioidosis